Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 11/20 | 0.50 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14772196 | 0.87 | PDE10A (0.48) | PDE10AGLRA1SPRHTT | |
| SCHEMBL11888917 | 0.87 | PDE10A (0.39) | PDE10AKMT2A | |
| SCHEMBL9104943 | 0.83 | SPR (0.42) | PDE10ASPR | |
| SCHEMBL31233502 | 0.81 | PDE10A (0.43) | PDE10AGLRA1SPR | |
| SCHEMBL9106126 | 0.80 | POLB (0.49) | PDE10A | |
| SCHEMBL1458202 | 0.80 | PDE10A (0.50) | PDE10A | |
| SCHEMBL11889069 | 0.79 | SPR (0.39) | PDE10AKMT2ASPRHTT | |
| SCHEMBL1457781 | 0.79 | PLAT (0.43) | PDE10AKMT2A | |
| SCHEMBL9104762 | 0.79 | L3MBTL1 (0.51) | PDE10AKMT2A | |
| SCHEMBL14672263 | 0.79 | POLB (0.47) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758396-B1 | TRIAZOLOPYRIDINE COMPOUNDS AS PDE10A INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-03-29 | — | — | EP | claimed |
| CN-103827114-B | Triazolopyridine compounds as PDE10A inhibitors | 霍夫曼-拉罗奇有限公司 | 2016-08-24 | — | — | CN | claimed |
| CN-103781768-B | Pde10 regulator | 霍夫曼-拉罗奇有限公司 | 2016-08-17 | — | — | CN | claimed |
| US-9227970-B2 | Triazolopyridine compounds | HOFFMANN-LA ROCHE, INC. (US) | 2016-01-05 | — | — | US | claimed |
| US-20150099735-A1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-04-09 | — | — | US | claimed |
| US-8946427-B2 | Triazolopyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2015-02-03 | — | — | US | claimed |
| US-20140303141-A1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2014-10-09 | — | — | US | claimed |
| EP-2758396-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PDE10A INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-30 | — | — | EP | claimed |
| US-8772510-B2 | PDE10 modulators | HOFFMANN-LA ROCHE INC. (US) | 2014-07-08 | — | — | US | claimed |
| WO-2013041472-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PDE10A INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-28 | — | — | WO | claimed |
| US-20130059833-A1 | PDE10 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | US | claimed |
| EP-2758396-B1 | TRIAZOLOPYRIDINE COMPOUNDS AS PDE10A INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-03-29 | — | — | EP | disclosed |
| CN-103827114-B | Triazolopyridine compounds as PDE10A inhibitors | 霍夫曼-拉罗奇有限公司 | 2016-08-24 | — | — | CN | disclosed |
| US-9227970-B2 | Triazolopyridine compounds | HOFFMANN-LA ROCHE, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| EP-2753604-B1 | PDE10 MODULATORS | HOFFMANN LA ROCHE (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-20110237564-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2011-09-29 | — | — | US | disclosed |
| US-20110237564-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2011-09-29 | — | — | US | disclosed |
| US-20110237564-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2011-09-29 | — | — | US | disclosed |
| WO-2011117264-A1 | N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011117264-A1 | N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303141-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PDE3A, PDE5A, PDE3B | PDE10A 5/4885GLRA1 2930/4885KMT2A 3176/4885 |
| US-20110237564-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | PDE5A, PDE3B, PDE3A | PDE10A 10/4885GLRA1 2730/4885KMT2A 2872/4885 |
| US-20130059833-A1 | PDE10 MODULATORS | PDE10A, PDE5A, PDE2A | PDE10A 1/4885GLRA1 959/4885KMT2A 2193/4885 |
| US-20150099735-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PDE3A, PDE5A, PDE3B | PDE10A 5/4885GLRA1 2930/4885KMT2A 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.